Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03848845
Title Study Evaluating Safety, Tolerability and Clinical Activity of GSK2857916 in Combination With Pembrolizumab in Subjects With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 4)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors GlaxoSmithKline

multiple myeloma


belantamab mafodotin-blmf + Pembrolizumab

Age Groups: adult | senior
Covered Countries USA | ESP | DEU | CAN

No variant requirements are available.